Market Cap 640.67B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 24.68
Forward PE 23.08
Profit Margin 28.46%
Debt to Equity Ratio 0.44
Volume 3,894,268
Avg Vol 7,661,946
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 73%
Beta 0.24
Analysts Strong Sell
Price Target $276.29

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
vermigli
vermigli Sep. 2 at 5:13 PM
$JNJ up over 32% YTD. UBS sets price target at $320. https://seekingalpha.com/news/4639561-jj-stock-at-all-time-high-ubs-assumes-buy 1 year dividend growth rate TTM is 4.38%. JNJ has grown the dividend for 63 consecutive years.
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 5:01 PM
$AZN $JNJ $MRK $PFE $SLS What does this mean for Big Pharmaceutical Suitors? GPS Curative 3 year plus Maintenance schedule for potentially 20+ WT1 cancers= $50 Billion annual peek sales and Dethrone patent expiring 2028 Keytruda as # 1 selling drug on the planet. ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 4:57 PM
$SLS $JNJ $AZN $MRK $PFE The real breakthrough is dual MHC Class I and Class II activation. Multivalency also ensures the cancer can't run. Together, they create a self-sustaining, polyclonal, living defense system inside the patient, one that hunts WT1-expressing cells for the rest of their life. And the 80% GPS responders? They aren't likely just surviving. They are functionally cured. Not managed. Not in fragile remission. CURED. With infinite dosing their T cells are still patrolling YEARS later. No cytokine storms. No need for a donor search. An off-the-shelf injection that reprograms immunity itself. ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 4:34 PM
$AZN $JNJ $LLY $MRK $SLS GPS Regal Pivotal Registrational Phase 3 Study Breakthrough results in AMLCR2/CRp2 is master key to unlock 20+ WT1 GPS Ad Infinitum Curative Platform. 👇 ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 4:18 PM
$AZN $JNJ $LLY $MRK $SLS With Warrants Extinguished and $SLS HTB/NTB (Hard To Borrow) (None To Borrow) 56 Million shares short, this is going to get really ugly for shorts in to the close EOD. Margin calls coming. 🔥 ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 4:11 PM
$AZN $JNJ $LLY $MRK $SLS 🤩 Major Blocks hitting the ASK now. 👇 ✌️❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 4:05 PM
$AZN $JNJ $LLY $MRK $SLS Massive Blocks going through Level 2 right now. 👇 ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 3:56 PM
$AZN $JNJ $LLY $MRK $SLS The American Association for Cancer Research (AACR) is widely considered one of the most prestigious and authoritative professional organizations in the global medical and scientific community.Reputation and ScaleWorld's Largest: Founded in 1907, it is the world's first and largest professional organization dedicated to advancing cancer research, boasting over 65,000 members across 143 countries and territories.Elite Membership: Its roster includes hundreds of Fellows of the AACR Academy, featuring dozens of Nobel laureates.High-Impact PublicationsTop-Tier Journals: The AACR publishes 10 peer-reviewed scientific journals, including highly influential and high-impact titles like Cancer Discovery, Cancer Research, and Clinical Cancer Research.Authoritative Forums: These journals are regarded as premier venues for publishing groundbreaking basic, translational, and clinical oncology research. ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 3:50 PM
$AZN $JNJ $LLY $MRK $SLS Today’s PR puts all major pharmaceutical eye balls on Sellas before GPS Regal Pivotal Registrational Phase 3 Breakthrough data. Let’s see if Big Pharmaceutical knocks Dr. Stergiou off tracks and make a move. ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 3:36 PM
$AZN $JNJ $LLY $MRK $SLS Sellas close money green $14.50+ too risky to go short over Labor Day weekend 3 day holiday with GPS Regal Pivotal Registrational Phase 3 data due up next= $120.00+ with multiple trading halts. ✌️🙏❤️‍🩹
0 · Reply
Latest News on JNJ
Johnson & Johnson assumed with a Buy at UBS

2026-09-02T11:35:52.000Z - 6 hours ago

Johnson & Johnson assumed with a Buy at UBS


China approves J&J's oral psoriasis pill, says drugmaker

Aug 27, 2026, 5:42 AM EDT - 6 days ago

China approves J&J's oral psoriasis pill, says drugmaker


Johnson & Johnson Transcript: Investor update

Aug 3, 2026, 8:00 AM EDT - 4 weeks ago

Johnson & Johnson Transcript: Investor update


Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Aug 2, 2026, 8:00 AM EDT - 4 weeks ago

Inside J&J's Lab to Create a Simpler Robotic Surgery Device


Johnson & Johnson lowers 2026 profit forecast

Jul 29, 2026, 5:38 PM EDT - 4 weeks ago

Johnson & Johnson lowers 2026 profit forecast


Explainer: Can J&J finally put the talc litigation behind it?

Jul 29, 2026, 12:01 PM EDT - 5 weeks ago

Explainer: Can J&J finally put the talc litigation behind it?


Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Jul 28, 2026, 12:26 PM EDT - 5 weeks ago

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits


J&J offers $5.5bn to settle baby powder lawsuits

Jul 28, 2026, 12:31 AM EDT - 5 weeks ago

J&J offers $5.5bn to settle baby powder lawsuits


DePuy Synthes Acquires Expanding Innovations™

Jul 16, 2026, 8:00 AM EDT - 6 weeks ago

DePuy Synthes Acquires Expanding Innovations™


Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 7 weeks ago

Johnson & Johnson Earnings Call Transcript: Q2 2026


Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 7 weeks ago

Johnson & Johnson Slides: Q2 2026


Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 7 weeks ago

Johnson & Johnson Earnings release: Q2 2026


Johnson & Johnson Quarterly report: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 7 weeks ago

Johnson & Johnson Quarterly report: Q2 2026


Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:35 AM EDT - 7 weeks ago

Johnson & Johnson Hikes Guidance, Stock Falls


Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:33 AM EDT - 7 weeks ago

Johnson & Johnson Bumps Up Guidance as Sales Rise


Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Jul 15, 2026, 6:20 AM EDT - 7 weeks ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook


The Big 3: UNH, KO, JNJ

Jul 9, 2026, 1:00 PM EDT - 7 weeks ago

The Big 3: UNH, KO, JNJ

KO UNH


vermigli
vermigli Sep. 2 at 5:13 PM
$JNJ up over 32% YTD. UBS sets price target at $320. https://seekingalpha.com/news/4639561-jj-stock-at-all-time-high-ubs-assumes-buy 1 year dividend growth rate TTM is 4.38%. JNJ has grown the dividend for 63 consecutive years.
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 5:01 PM
$AZN $JNJ $MRK $PFE $SLS What does this mean for Big Pharmaceutical Suitors? GPS Curative 3 year plus Maintenance schedule for potentially 20+ WT1 cancers= $50 Billion annual peek sales and Dethrone patent expiring 2028 Keytruda as # 1 selling drug on the planet. ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 4:57 PM
$SLS $JNJ $AZN $MRK $PFE The real breakthrough is dual MHC Class I and Class II activation. Multivalency also ensures the cancer can't run. Together, they create a self-sustaining, polyclonal, living defense system inside the patient, one that hunts WT1-expressing cells for the rest of their life. And the 80% GPS responders? They aren't likely just surviving. They are functionally cured. Not managed. Not in fragile remission. CURED. With infinite dosing their T cells are still patrolling YEARS later. No cytokine storms. No need for a donor search. An off-the-shelf injection that reprograms immunity itself. ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 4:34 PM
$AZN $JNJ $LLY $MRK $SLS GPS Regal Pivotal Registrational Phase 3 Study Breakthrough results in AMLCR2/CRp2 is master key to unlock 20+ WT1 GPS Ad Infinitum Curative Platform. 👇 ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 4:18 PM
$AZN $JNJ $LLY $MRK $SLS With Warrants Extinguished and $SLS HTB/NTB (Hard To Borrow) (None To Borrow) 56 Million shares short, this is going to get really ugly for shorts in to the close EOD. Margin calls coming. 🔥 ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 4:11 PM
$AZN $JNJ $LLY $MRK $SLS 🤩 Major Blocks hitting the ASK now. 👇 ✌️❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 4:05 PM
$AZN $JNJ $LLY $MRK $SLS Massive Blocks going through Level 2 right now. 👇 ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 3:56 PM
$AZN $JNJ $LLY $MRK $SLS The American Association for Cancer Research (AACR) is widely considered one of the most prestigious and authoritative professional organizations in the global medical and scientific community.Reputation and ScaleWorld's Largest: Founded in 1907, it is the world's first and largest professional organization dedicated to advancing cancer research, boasting over 65,000 members across 143 countries and territories.Elite Membership: Its roster includes hundreds of Fellows of the AACR Academy, featuring dozens of Nobel laureates.High-Impact PublicationsTop-Tier Journals: The AACR publishes 10 peer-reviewed scientific journals, including highly influential and high-impact titles like Cancer Discovery, Cancer Research, and Clinical Cancer Research.Authoritative Forums: These journals are regarded as premier venues for publishing groundbreaking basic, translational, and clinical oncology research. ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 3:50 PM
$AZN $JNJ $LLY $MRK $SLS Today’s PR puts all major pharmaceutical eye balls on Sellas before GPS Regal Pivotal Registrational Phase 3 Breakthrough data. Let’s see if Big Pharmaceutical knocks Dr. Stergiou off tracks and make a move. ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 3:36 PM
$AZN $JNJ $LLY $MRK $SLS Sellas close money green $14.50+ too risky to go short over Labor Day weekend 3 day holiday with GPS Regal Pivotal Registrational Phase 3 data due up next= $120.00+ with multiple trading halts. ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 2:36 PM
$SLS $JNJ $AZN $MRK 😆 you think they will wait again like $RVMD and $RVMD MC shot up $20 Billion in first 3 hours of trading after their PDAC data and now is $46 Billion. ✌️🙏❤️‍🩹
0 · Reply
Stocktwits
Stocktwits Sep. 2 at 2:21 PM
$JNJ with a fresh 52-week high today
0 · Reply
frb1985
frb1985 Sep. 2 at 2:12 PM
$JNJ is that another all time high. 😃
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 2:12 PM
$AZN $JNJ $RVMD $MRK $SLS Part 2. Big Pharmaceuticals will not make the same mistake like they did with $RVMD and now Revmed is worth over $45 Billion MC. Don’t be surprised you all come for the GPS Regal Phase 3 Breakthrough data but a T1 halt hits and the this 13 FTE company is BO! ✌️🙏❤️‍🩹
0 · Reply
Estimize
Estimize Sep. 2 at 2:12 PM
Wall St is expecting 2.90 EPS for $JNJ Q3 [Reporting 10/13 BMO] http://www.estimize.com/intro/jnj?chart=historical&metric_name=eps&utm_cont
0 · Reply
CHARTBUSTER12
CHARTBUSTER12 Sep. 2 at 2:08 PM
$JNJ good morning my friends JNJ is doing as i have predicted going higher this company has great leadership and lot's of good thing coming in 2026. my friends three stocks i watching JNJ,SLS, and a new watchlist for me but good BIO COMPANY RNXT which i see is growing fast and could be the next big runner over $10 this year. have a blessed day of trading
0 · Reply
Stocktwits52wHighs
Stocktwits52wHighs Sep. 2 at 2:01 PM
$JNJ printed a new 52-week high today
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 2:01 PM
$AZN $JNJ $LLY $MRK $SLS Mr. Cavanaugh from $JNJ took over yesterday. $JNJ is my # 1 pick for Sellas BO! ✌️🙏❤️‍🩹
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Sep. 2 at 1:57 PM
0 · Reply
BioTechBling
BioTechBling Sep. 2 at 1:05 PM
$AZN $JNJ $LLY $MRK $SLS The Scientific, Medical & Pharma communities CARE VERY MUCH about the pre-clinical DATA! Anyone who’s is impatient & in $£$ just for the $$$ can sell already up 100’s-1000’s%… don’t let the door hit you on the way out.
0 · Reply
Duncan74
Duncan74 Sep. 2 at 1:02 PM
$SLS I feel the frustration on the wait, but you are completely missing the strategic brilliance of this timing. The fact that we are stuck waiting means the 48 long-term survivors are on an extended plateau. Every week that passes without a death increases the median Overall Survival tail of the GPS arm, driving the final Hazard Ratio down to historic levels. Dropping the 3 AACR pancreatic posters for the Sept 25–28 conference isn't fluff—it's a deliberate M&A billboard for $MRK,and $JNJ. By officially proving that SLS009 breaks the resistance walls of $RVMD’s $44B RAS canopy, Stergiou is showing Big Pharma that they aren't just bidding on a niche leukemia drug —they are bidding on a universal, multi-asset oncology empire right before the REGAL data locks. The wait is maximizing the final buyout valuation. 😎
2 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 12:57 PM
$AZN $JNJ $LLY $MRK $SLS Dew, within Next 3 business days. Mark this post! ✌️🙏❤️‍🩹
2 · Reply